Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taron

Showing results (321-330 of 327) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 327 results.
Nature Genetics|July 4, 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerZhenfeng Zhang, Jae Cheol Lee, Luping Lin, et al.
Science (New York, N.Y.)|March 6, 2025
Rapid butterfly declines across the United States during the 21st centuryCollin B Edwards, Elise F Zipkin, Erica H Henry, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Latent plasticity of the human pancreas across development, health, and diseaseElisabetta Mereu, Diego Balboa, Johannes Liebig, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Nature|June 29, 2022
Grey wolf genomic history reveals a dual ancestry of dogsAnders Bergström, David W G Stanton, Ulrike H Taron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 33

Showing results (321-330 of 327) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 327 results.
Nature Genetics|July 4, 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerZhenfeng Zhang, Jae Cheol Lee, Luping Lin, et al.
Science (New York, N.Y.)|March 6, 2025
Rapid butterfly declines across the United States during the 21st centuryCollin B Edwards, Elise F Zipkin, Erica H Henry, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Latent plasticity of the human pancreas across development, health, and diseaseElisabetta Mereu, Diego Balboa, Johannes Liebig, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Nature|June 29, 2022
Grey wolf genomic history reveals a dual ancestry of dogsAnders Bergström, David W G Stanton, Ulrike H Taron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 33